Analysis Tools|
Allele Symbol Allele Name Allele ID |
Supv3l1tm2Jkl targeted mutation 2, Jan Klysik MGI:3833740 |
||||||||||||||||
| Summary |
3 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
Kyphosis and scaling on feet develop in Supv3l1tm2Jkl/Supv3l1tm2Jkl Tg(CAG-cre/Esr1*)5Amc/0 mice following tamoxifen treatment
|
• mice die by 15 weeks of age
• tamoxifen-treated mice die by 6 weeks of age
|
|
• in the lungs in tamoxifen-treated mice
|
|
• mice exhibit thymic atrophy that develops more rapidly in tamoxifen treated mice
|
|
• 6-fold in tamoxifen-treated mice compared to mice heterozygous for the floxed allele
|
|
• tamoxifen-treated mice exhibit decreased DN2, DN3, and DN4 cells compared to mice heterozygous for the floxed allele
|
|
• in tamoxifen-treated mice
|
|
• more than 10-fold in tamoxifen-treated mice
|
|
• in tamoxifen-treated mice
|
|
• in tamoxifen-treated mice
|
|
• chronic and acute in untreated and tamoxifen-treated mice
|
|
• in tamoxifen-treated mice
|
|
• mice exhibit adipose tissue loss that develops more rapidly in tamoxifen treated mice
|
|
• chronic and acute in untreated and tamoxifen-treated mice
|
|
• thickened in in tamoxifen-treated mice and untreated mice
|
|
• mice exhibit sarcopenia atrophy that develops more rapidly in tamoxifen treated mice
|
|
• mice exhibit thymic atrophy that develops more rapidly in tamoxifen treated mice
|
|
• 6-fold in tamoxifen-treated mice compared to mice heterozygous for the floxed allele
|
|
• in tamoxifen-treated mice, the numbers of sebaceous glands is reduced compared to in untreated mice
|
|
• tamoxifen-treated mice exhibit focal vascular ectasia in the skin unlike in untreated mice
• mice treated topically with tamoxifen exhibit dilated vasculature at the site of application
|
|
• locomotor functions fail in moribund mice
|
|
• tamoxifen-treated mice exhibit an increase in apoptosis compared to untreated mice
|
|
• in the lungs in tamoxifen-treated mice
|
|
• mice exhibit thymic atrophy that develops more rapidly in tamoxifen treated mice
|
|
• 6-fold in tamoxifen-treated mice compared to mice heterozygous for the floxed allele
|
|
• tamoxifen-treated mice exhibit decreased DN2, DN3, and DN4 cells compared to mice heterozygous for the floxed allele
|
|
• in tamoxifen-treated mice
|
|
• more than 10-fold in tamoxifen-treated mice
|
|
• in tamoxifen-treated mice
|
|
• in tamoxifen-treated mice
|
|
• in the lungs in tamoxifen-treated mice
|
| N |
• unlike in Supv3l1tm2Jkl/Supv3l1tm2Jkl floxed Tg(Mx1-cre)1Cgn mice, tamoxifen-treated mice exhibit normal hair growth
|
|
• mice exhibit adipose tissue loss that develops more rapidly in tamoxifen treated mice
|
|
• in tamoxifen-treated mice, the numbers of sebaceous glands is reduced compared to in untreated mice
|
|
• tamoxifen treated mice exhibit focal vascular ectasia, reduced adipose tissue, and atrophic muscle layer in the skin unlike in untreated mice
|
|
• apoptosis rates in the basal layer are increased in tamoxifen-treated mice compared to in untreated mice
|
|
• mild in tamoxifen-treated mice and at the site of application in mice treated topically with tamoxifen
|
|
• at the site of tamoxifen application when applied directly to the skin
|
|
• hypergranulosis develops in tamoxifen-treated mice and at the site of application in mice treated topically with tamoxifen
|
|
• in tamoxifen-treated mice
|
|
• in tamoxifen-treated mice and at the site of tamoxifen application when applied directly to the skin
|
|
• at the site of tamoxifen application when applied directly to the skin
|
|
• on the skin and tails of tamoxifen-treated mice and at the site of tamoxifen application when applied directly to the skin
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
Disfigured ears, abdominal alopecia and scales on feet in Supv3l1tm2Jkl/Supv3l1tm2Jkl Tg(Mx1-cre)1Cgn/0 mice
|
• some mice become moribund at 4 weeks of age while others live up to 10 weeks
|
|
• in the red pulp of the liver
|
|
• in the red pulp of the liver
|
|
• 50% of wild-type at 4 weeks
|
|
• at weaning, mice exhibit slower growth than wild-type mice
|
|
• in moribund mice
|
|
• mice exhibit a thickened interstitium with infiltration by inflammatory cells and occasionally foamy macrophages
|
|
• in moribund mice
|
|
• the number of sebaceous glands is decreased compared to in wild-type mice
|
|
• dilated vessels are found in the dermal layer of cells of the ear unlike in wild-type mice
|
|
• locomotor functions fail in moribund mice
|
|
• at weaning mice have flattened and disfigured ears compared to in wild-type mice
|
|
• in the red pulp of the liver
|
|
• in the red pulp of the liver
|
|
• in the red pulp of the liver
|
|
• the number of sebaceous glands is decreased compared to in wild-type mice
|
|
• at weaning, mice exhibit abnormal appearance and density of coat hairs compared to in wild-type mice
|
|
• some mice exhibit mild dermal acute inflammatory infiltrate unlike in wild-type mice
• the dermal layer is atrophic unlike in wild-type mice
|
|
• dyskeratosis (apoptosis) is increased in the basal cell layer and mid-epidermis compared to in wild-type mice
|
|
• severe
|
|
• on the dorsal and abdominal skin
|
|
• after 6 weeks mice exhibit scaly dorsal and abdominal skin, feet, tail, and ears
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 12/10/2024 MGI 6.24 |
|
|
|
||
